If brand-name Wegovy or Ozempic is affordable for you (typically with insurance coverage or a manufacturer savings program), that is the path with the strongest regulatory backing
what fails is a consistent process for capturing insulin use at the point of care and reconciling it across encounters
Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist licensed in the UK for the treatment of type 2 diabetes mellitus and, at higher doses (marketed as Wegovy), for weight management in adults with obesity or overweight with comorbidities
That can feel empowering
Marso, S.P., Bain, S.C., Consoli, A., Eliaschewitz, F.G., Jdar, E., Leiter, L.A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M.L., Woo, V., Hansen, O., Holst, A.G., Pettersson, J., Vilsbll, T